Objectives. To determine overexpression of p53, EGFR, c-erbB-2 and c-erbB-3 in endometrioid carcinoma of the ovary and to evaluate the prognostic significance of these results, especially, coexisting overexpression of...Objectives. To determine overexpression of p53, EGFR, c-erbB-2 and c-erbB-3 in endometrioid carcinoma of the ovary and to evaluate the prognostic significance of these results, especially, coexisting overexpression of p53 and one of the member of type I growth factor receptor family.Methods. Overexpressions of the p53, EGFR, c-erbB-2 and c-erbB-3 protein were studied by im-munohistochemistry in paraffin-embedded tumor tissue from 28 patients with endometrioid carcinoma of the ovary.Results. 11 (39.3%), 13 (46. 4%), and 14 (50. 0%) were stained positively with p53, c-erbB-2 and c-erbB-3 monoclonal antibodies. 13 (46- 4%) was stained positively with EGFR polyclonal antibody. There were no relationship between p53, EGFR, C-erbB-2, c-erbB-3 and histologic grade, lymph node metastasis. The percentage of tumors with over expression of p53, EGFR, C-erbB-2 and c-erbB-3 was higher in those with stage Ⅱ-Ⅲ tumors compared with those with stage Ⅰ , in patients with residual tumor after initial surgery compared with those without. A high survival rate was observed in patients without p53, EGFR, c-erbB-2 and c-erbB-3 overexpression respectively than those with. A highest survival rate was observed in patients with both p53 and one of EGFR, c-erbB-2 and c-erbB-3 negative compared with those both positive or either of both positive.Conclusion. Overexpression of p53, EGFR, c-erbB-2 and C-erbB-3 resulted in a poorer prognosis respectively. Overexpression of both p53 and one of the EGFR, c-erbB-2 and c-erbB-3 is a worse prognostic indicator in patients with endometrioid carcinoma of the ovary.展开更多
目的：探讨乳腺癌钼靶X线钙化与ER、PR及c-erbB-2表达的相关性及其临床意义.方法：分析86例乳腺癌钼靶X线片,将其分为有钙化组（46例）和无钙化组（40例） 将切除的肿瘤标本行HE及免疫组织化学染色,检测并比较两组ER、PR和c-erbB-2的表...目的：探讨乳腺癌钼靶X线钙化与ER、PR及c-erbB-2表达的相关性及其临床意义.方法：分析86例乳腺癌钼靶X线片,将其分为有钙化组（46例）和无钙化组（40例） 将切除的肿瘤标本行HE及免疫组织化学染色,检测并比较两组ER、PR和c-erbB-2的表达率.结果：乳腺癌钼靶X线有钙化组ER和PR的表达率均略高于无钙化组（56.5% vs 55.0%,45.6% vs 42.5% ）,但差异无统计学意义 （P＞0. 05） 有钙化组c-erbB-2表达率高于无钙化组（65.2% vs 40.0%）,差异有统计学意义（P＜0. 05）.结论：乳腺癌钼靶X线钙化与ER、PR表达无相关性,但与c-erbB-2表达密切相关 钼靶X线钙化可以粗略反映c-erbB-2表达情况,可为乳腺癌治疗策略的制定和预测预后提供参考.展开更多
文摘Objectives. To determine overexpression of p53, EGFR, c-erbB-2 and c-erbB-3 in endometrioid carcinoma of the ovary and to evaluate the prognostic significance of these results, especially, coexisting overexpression of p53 and one of the member of type I growth factor receptor family.Methods. Overexpressions of the p53, EGFR, c-erbB-2 and c-erbB-3 protein were studied by im-munohistochemistry in paraffin-embedded tumor tissue from 28 patients with endometrioid carcinoma of the ovary.Results. 11 (39.3%), 13 (46. 4%), and 14 (50. 0%) were stained positively with p53, c-erbB-2 and c-erbB-3 monoclonal antibodies. 13 (46- 4%) was stained positively with EGFR polyclonal antibody. There were no relationship between p53, EGFR, C-erbB-2, c-erbB-3 and histologic grade, lymph node metastasis. The percentage of tumors with over expression of p53, EGFR, C-erbB-2 and c-erbB-3 was higher in those with stage Ⅱ-Ⅲ tumors compared with those with stage Ⅰ , in patients with residual tumor after initial surgery compared with those without. A high survival rate was observed in patients without p53, EGFR, c-erbB-2 and c-erbB-3 overexpression respectively than those with. A highest survival rate was observed in patients with both p53 and one of EGFR, c-erbB-2 and c-erbB-3 negative compared with those both positive or either of both positive.Conclusion. Overexpression of p53, EGFR, c-erbB-2 and C-erbB-3 resulted in a poorer prognosis respectively. Overexpression of both p53 and one of the EGFR, c-erbB-2 and c-erbB-3 is a worse prognostic indicator in patients with endometrioid carcinoma of the ovary.
文摘目的：探讨乳腺癌钼靶X线钙化与ER、PR及c-erbB-2表达的相关性及其临床意义.方法：分析86例乳腺癌钼靶X线片,将其分为有钙化组（46例）和无钙化组（40例） 将切除的肿瘤标本行HE及免疫组织化学染色,检测并比较两组ER、PR和c-erbB-2的表达率.结果：乳腺癌钼靶X线有钙化组ER和PR的表达率均略高于无钙化组（56.5% vs 55.0%,45.6% vs 42.5% ）,但差异无统计学意义 （P＞0. 05） 有钙化组c-erbB-2表达率高于无钙化组（65.2% vs 40.0%）,差异有统计学意义（P＜0. 05）.结论：乳腺癌钼靶X线钙化与ER、PR表达无相关性,但与c-erbB-2表达密切相关 钼靶X线钙化可以粗略反映c-erbB-2表达情况,可为乳腺癌治疗策略的制定和预测预后提供参考.
